CF102: Preliminary Phase I/II data

In an open-label, dose-escalation, Israeli Phase I/II trial, twice-daily oral CF102 significantly reduced HCV viral load in 3 of 4 evaluable patients with advanced HCC who were HCV-positive with a cir...